Gilles Brisson - Mauna Kea Insider

MKEA -- France Stock  

EUR 3.10  0.16  5.44%

Mr. Gilles Brisson was Chairman of the Board and Independent Director of Mauna Kea Technologies SA since March 5 2012. He is Member of the Company Audit Committee and Remuneration Committee. He has served in various roles during his 20year tenure at RhonePoulenc Rorer including Senior VicePresident of Corporationrationrate Development. He led Aventis French pharmaceutical business from 1999 to 2003 as President and Chief Executive Officer. Then he became Senior Vice President of Europe for Aventis and Sanofi aventis. Mr. Brisson was Chairman of the Supervisory Board of Innate Pharma since 2007 and of Ethypharm since 2009.
Age: 61  Chairman Since 2012      
33 1 48 24 03 45

Management Efficiency

The company has return on total asset (ROA) of (25.43) % which means that it has lost $25.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (73.44) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.95 M in total debt with debt to equity ratio (D/E) of 41.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 5.67 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 5 records


Olivier JallabertAmplitude Surgical SA
Eric BeardCellnovo Limited
Hermann RequardtSuperSonic Imagine SA
Fredrik BragMedian Technologies SA
Gerard HascoetEOS imaging SA

Entity Summary

Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Devices classification in France and traded on Paris Stock Exchange. It employs 90 people.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 90 people.

Mauna Kea Technologies Leadership Team

Olivier Regnard, Deputy CEO, CFO
Bertrand Talhouet, Representative of Creadev on the Board of Directors
Eric Cohen, CFO and VP of Fin.
Gilles Brisson, Chairman, Independent Director
Alexandre Loiseau, CEO, Director
Guillaume Bailliard, President for North America
Christopher McFadden, Director
Francois Lacombe, Chief Scientific Officer
Christopher Tihansky, Chief Devel. Officer and President of North America
JeanLuc Boulnois, Director
Bruno Villaret, Vice President of International Sales
Joseph DeVivo, Non-Executive Independent Director
Christophe Bailleul, Vice-President Clinical Affairs, Health Economics and Market Access
Agnes Rouffiac, Director of Human Resources
Veronique Dentan, Director of Operations
Sebastien Cadet, Global Director of Marketing and OEM Leader
Sacha Loiseau, Founder, CEO and Director
Molly ONeill, Director
Pierre Forest, COO
John Soto, COO
Marie Meynadier, Director

Stock Performance Indicators

Did you try this?

Run Instant Ratings Now


Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Instant Ratings

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.